RHOXF1

Across TCGA pan-cancer cohorts, RHOXF1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RHOXF1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RHOXF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RHOXF1 expression acts as an unfavorable survival marker.

BLCA, SCLC, and SKCM are the cancer types where RHOXF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.161	0.609	.008	27	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
SKCM	OS	Median	All	0.230	0.784	<.001	12	view →
UCS	OS	Median	All	0.179	0.584	.024	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	II,III,IV	0.287	0.719	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RHOXF1–BLCA (OS)

Open the BLCA breakdown →